Выбор редакции

Pharmacyclics ([[PCYC]] -4.4%) slips after being downgraded to Market Perform at Leerink Swann on the back of its recent run. Leerink says that a number of key catalysts have already been realized, and further upside beyond its current valuation while possible, will require stronger sales numbers from ibrutinib than what's currently available. The firm raised its price target on the stock to $97 from $80.

Pharmacyclics (PCYC -4.4%) slips after being downgraded to Market Perform at Leerink Swann on the back of its recent run. Leerink says that a number of key catalysts have already been realized, and further upside beyond its current valuation while possible, will require stronger sales numbers from ibrutinib than what's currently available. The firm raised its price target on the stock to $97 from $80. Post your comment!

НОВОСТИ ПО ТЕМЕ